Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020 – Business…
Posted: September 21, 2020 at 1:55 am
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that it presented the latest results from three Phase III studies from the Tecentriq (atezolizumab) clinical development program in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease, said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. We are proud of our work to address challenges and advance scientific understanding of cancer immunotherapy in the context of distinct chemotherapy regimens and in various TNBC treatment settings. Although the IMpassion131 study did not reach its endpoint, we are pleased to bring new treatment options for some TNBC patients, and remain committed to improving the lives of all women with early and advanced stages of this disease.
Results from the Phase III IMpassion031 study, evaluating Tecentriq in combination with chemotherapy (Abraxane [albumin-bound paclitaxel; nab-paclitaxel]; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chemotherapy (including nab-paclitaxel) demonstrated a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early TNBC, regardless of PD-L1 expression. pCR was observed in 57.6% (95% CI: 49.7-65.2) of patients treated with Tecentriq in combination with chemotherapy, an increase of 16.5% from 41.1% (95% CI: 33.6-48.9) in patients treated with placebo plus chemotherapy (one-sided p=0.0044, significance boundary = 0.0184) in the intention-to-treat (ITT) population. The safety profile was consistent with the established profile of the individual medicines and no new safety concerns were identified.
The IMpassion031 study is the second positive Phase III study from Genentech demonstrating the benefit of Tecentriq in TNBC, and the first Tecentriq study to demonstrate benefit in early TNBC. Tecentriq in combination with nab-paclitaxel is currently approved in more than 70 countries worldwide, including the United States and across Europe, for the treatment of adults with unresectable locally advanced or metastatic TNBC in people whose tumors express PD-L1 (IC1%).
The final overall survival (OS) analysis of the Phase III IMpassion130 study, evaluating Tecentriq in combination with nab-paclitaxel compared with placebo plus nab-paclitaxel as a first-line treatment for patients with metastatic TNBC, was consistent with the first and second interim analyses. There was no significant difference in OS between the treatment groups in the ITT population. Clinically meaningful improvements in OS were seen with Tecentriq plus nab-paclitaxel in PD-L1-positive patients. The magnitude of OS improvements with Tecentriq in PD-L1-positive patients remained clinically meaningful, with an increase of 7.5 months in median OS with Tecentriq plus nab-paclitaxel compared with placebo plus nab-paclitaxel (hazard ratio [HR]=0.67 [95% CI: 0.530.86]). However, this result could not be formally tested due to the prespecified statistical testing hierarchy. The cumulative safety of the Tecentriq plus nab-paclitaxel combination remains consistent with the previously reported safety data for this study and the known risks of individual study medicines. No new safety concerns were identified with longer follow-up.
Finally, results from the Phase III IMpassion131 study, evaluating Tecentriq in combination with paclitaxel compared with placebo plus paclitaxel as a first-line treatment for patients with metastatic TNBC, did not show significant improvement for progression-free survival (PFS) in the PD-L1-positive population (HR=0.82 [95% CI: 0.60-1.12]). The OS data showed a negative trend; however, the study was not powered for the secondary endpoint of OS, and OS data were immature at the time of analysis (initial HR=1.55 [95% CI: 0.86-2.80] in the PD-L1-positive population, based on 21% of patients with an event; updated HR=1.12 [95% CI: 0.76-1.65], updated analysis based on 41% of patients with an event). The safety profile of Tecentriq plus paclitaxel was consistent with the established safety profile of the individual study medicines and no new safety concerns were identified.
Genentech has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across several types of lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.
About the IMpassion031 study
The IMpassion031 study is a Phase III, multi-center, randomized, double-blind study evaluating the efficacy and safety of Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [albumin-bound paclitaxel; nab-paclitaxel]; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chemotherapy, in people with previously untreated, early TNBC. The primary endpoint is pCR using the American Joint Committee on Cancer (AJCC) staging system in the intention-to-treat (ITT) population and in the PD-L1-positive population. Secondary endpoints include overall survival (OS), event-free survival, disease-free survival and quality of life measures.
About the IMpassion130 study
The IMpassion130 study is a Phase III, multicenter, randomized, double-blind study evaluating the efficacy, safety and pharmacokinetics of Tecentriq plus nab-paclitaxel compared with placebo plus nab-paclitaxel in people with unresectable locally advanced or metastatic TNBC who have not received prior systemic therapy for metastatic breast cancer. The study enrolled 902 people who were randomized equally (1:1). The co-primary endpoints are PFS per investigator assessment (RECIST 1.1), and OS in the ITT population and PD-L1-positive population. Secondary endpoints include objective response rate and duration of response.
About the IMpassion131 study
The IMpassion131 study is a Phase III, multi-center, randomized, double-blind study evaluating the efficacy and safety of Tecentriq in combination with paclitaxel, in comparison to placebo plus paclitaxel, in people with previously untreated, inoperable, locally advanced or metastatic TNBC. The study enrolled 651 people who were randomized in a 2:1 ratio to receive Tecentriq or placebo plus paclitaxel. The primary endpoint is PFS per investigator assessment (RECIST 1.1) in the PD-L1-positive population, followed by intention-to-treat (ITT) population. Secondary endpoints include OS, objective response rate, and duration of response in the PD-L1-positive and ITT populations.
About triple-negative breast cancer
Breast cancer is the most common cancer among women worldwide. According to the American Cancer Society, close to 280,000 people in the United States will be diagnosed with invasive breast cancer, and more than 42,000 will die from the disease in 2020. Breast cancer is not one, but many diseases based on the biology of each tumor. In triple-negative breast cancer, tumor cells lack hormone receptors and do not have excess HER2 protein. Approximately 15 percent of breast cancers are triple-negative based on the results of diagnostic tests. It is an aggressive form of the disease with few treatment options.
About Tecentriq (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.
Tecentriq U.S. Indications (pronounced t-SEN-trik)
Tecentriq is a prescription medicine used to treat adults with:
A type of bladder and urinary tract cancer called urothelial carcinoma.
Tecentriq may be used in patients with urothelial carcinoma if their bladder cancer has spread or cannot be removed by surgery, and if they have any one of the following conditions:
The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients disease worsened. Continued approval for this use may depend on the results of an ongoing study to confirm benefit.
A type of lung cancer called non-small cell lung cancer (NSCLC).
Tecentriq may be used alone as the first treatment in patients with lung cancer if:
Tecentriq may be used with the medicines bevacizumab, paclitaxel, and carboplatin as the first treatment in patients with lung cancer if:
Tecentriq may be used with the medicines paclitaxel protein-bound and carboplatin as the first treatment in patients with lung cancer if:
Tecentriq may be used alone in patients with lung cancer if:
A type of breast cancer called triple-negative breast cancer (TNBC).
Tecentriq may be used with the medicine paclitaxel protein-bound in patients with TNBC when their breast cancer:
The approval of Tecentriq in these patients is based on a study that measured the amount of time until patients disease worsened. Continued approval for this use may depend on the results of an ongoing study to confirm benefit.
A type of lung cancer called small cell lung cancer (SCLC).
A type of liver cancer called hepatocellular carcinoma (HCC).
Tecentriq may be used with the medicine bevacizumab when a patients liver cancer:
A type of skin cancer called melanoma.
Tecentriq may be used with the medicines cobimetinib and vemurafenib when a patients melanoma:
It is not known if Tecentriq is safe and effective in children.
Important Safety Information
The most important information about Tecentriq is:
Tecentriq can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.
Patients should call or see their healthcare provider right away if they get any symptoms of the following problems or these symptoms get worse.
Tecentriq can cause serious side effects, including:
Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may delay or completely stop treatment with Tecentriq if patients have severe side effects.
Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:
Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of Tecentriq when used alone include:
The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include:
The most common side effects of Tecentriq when used in TNBC with paclitaxel protein-bound include:
The most common side effects of Tecentriq when used in hepatocellular carcinoma with bevacizumab include:
The most common side effects of Tecentriq when used in melanoma with cobimetinib and vemurafenib include:
Tecentriq may cause fertility problems in females, which may affect their ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.
These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information. Patients should call their doctor for medical advice about side effects of Tecentriq.
Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.
Please visit http://www.Tecentriq.com for the full Tecentriq Prescribing Information for additional Important Safety Information.
About Genentech in cancer immunotherapy
Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus. With more than 20 immunotherapy molecules in development, Genentech is investigating the potential benefits of immunotherapy alone, and in combination with various chemotherapies, targeted therapies and other immunotherapies with the goal of providing each person with a treatment tailored to harness their own unique immune system.
In addition to Genentechs approved PD-L1 checkpoint inhibitor, the companys broad cancer immunotherapy pipeline includes other checkpoint inhibitors, individualized neoantigen therapies and T cell bispecific antibodies. For more information visit http://www.gene.com/cancer-immunotherapy.
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
Read the original:
Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020 - Business...
- Last Call with Jenna Balestrini, the WPI grad treating cancer with cell therapy - Worcester Mag - January 14th, 2021
- Province gives family facing $2.8M drug bill a glimmer of hope - CBC.ca - January 14th, 2021
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- This 6-year-old Iowa boy is losing his vision and hearing. But his family holds on to hope. - The Gazette - December 22nd, 2020
- What Is Gene Therapy? How Does It Work? | FDA - December 17th, 2020
- What is gene therapy? - The Star Online - December 17th, 2020
- What It's Like Rising A Little Boy With Advanced Breast Cancer - Oprah Mag - December 17th, 2020
- EAPM Advancing gene therapy with Advanced Therapy Medicinal Products - EU Reporter - December 16th, 2020
- San Diego's Locanabio raises $100 million for treatments aimed at degenerative diseases - The San Diego Union-Tribune - December 16th, 2020
- Italy needs new restrictions to avoid third, devastating COVID-19 wave - PM to paper - EU Reporter - December 16th, 2020
- Yes, men can get breast cancer here are the symptoms to watch for - Insider - INSIDER - December 12th, 2020
- Mumbai: Baby with genetic disorder needs Rs 16 crore therapy to live - Mid-day - December 12th, 2020
- Gene Therapy Liberates Hemophilia B Patients from Requiring Regular Infusions of Clotting Factor - MedicalResearch.com - December 12th, 2020
- Vaccination in the Era of Covid - Touro College News - December 7th, 2020
- Genentech Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Based Combination for People With Relapsed or Refractory Chronic... - December 7th, 2020
- Medicare and cystic fibrosis: Coverage, options, treatments, and costs - Medical News Today - December 7th, 2020
- The FDA has approved the first drug to treat the rapid-aging disease progeria - Science News - November 26th, 2020
- 'This is why I'm here': A Detroit Lions VP tries to save her daughter from rare disease - ESPN - November 24th, 2020
- Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG - OncoZine - November 24th, 2020
- SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders - Business Wire - November 24th, 2020
- SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders - BioSpace - November 23rd, 2020
- Rare Mutation in the PCSK9 Gene Confers Long Healthy Life - MedicalResearch.com - November 23rd, 2020
- Living through the second wave - Pakistan Today - November 23rd, 2020
- How two blind brothers became Two Blind Brothers for a cause - The Columbian - November 10th, 2020
- How two blind brothers created a one-of-a-kind shopping experience to raise money for a cure - WXII The Triad - November 10th, 2020
- The ethical way to alter organisms - The Boston Globe - November 10th, 2020
- Teladoc Is A Strong Buy: A Radical Healthcare Change Will Come - Seeking Alpha - November 10th, 2020
- Medical Milestone In Boston: 13-Year-Old Gets New Gene ... - November 5th, 2020
- How immunotherapy is revolutionizing cancer care - Genetic Literacy Project - October 29th, 2020
- The good news about breast cancer - The Gazette - October 29th, 2020
- Harris County parents win insurance appeal for 8-year-olds MD treatment - WRBL - October 29th, 2020
- Biohack the ageing process by taking care of this little protein in your body - Lifestyle Asia - October 22nd, 2020
- 'I have faith and I prayed a lot' - News from southeastern Connecticut - theday.com - October 22nd, 2020
- Piqray Improves Overall Survival for Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation - Breastcancer.org - October 20th, 2020
- Beating Cancer: Prevention must be 'cornerstone' of EU's new approach - The Parliament Magazine - October 20th, 2020
- Watch: New 5-minute injection a game-changer in breast cancer therapy in UAE - Gulf News - October 20th, 2020
- Homer Glen Mom and Nurse Breast Cancer-Free after Radiation Therapy Clinical Trial at UChicago Medicine Comprehensive Cancer Center at Silver Cross -... - October 20th, 2020
- Teenager among first to receive gene therapy treatment for rare condition - KRDO - October 8th, 2020
- Proposition 14: With Just Handful of Cures, California Stem Cell Agency's Fate Is In Hands of Voters - KQED - October 8th, 2020
- Teenager among first to receive gene therapy treatment for rare condition - NewsChannel 3-12 - KEYT - October 7th, 2020
- Greenbrier County teen to be among first in nation to receive gene therapy for Hurler's Syndrome - WVVA TV - October 7th, 2020
- Regenxbio RGX-121 Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha - October 7th, 2020
- Women In Longevity Medicine And The Rise Of The Longevity Physician - Forbes - October 7th, 2020
- Timothy Ray Brown, First Patient to Be Cured of HIV, Dies of Leukemia - BioSpace - October 7th, 2020
- Different Types of Childhood Cancer | INTEGRIS - Integris - October 4th, 2020
- Gene therapy company Taysha completes sprint from first funding to IPO - BioPharma Dive - September 26th, 2020
- Focused on the future: Innovative college programs in N.J. pave way for the real world - Jersey's Best - September 24th, 2020
- Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH - Medscape - September 22nd, 2020
- 10 Forgotten Spiderman Sidekicks They Need To Bring Back | CBR - CBR - Comic Book Resources - September 22nd, 2020
- BCS Announces Partnership With 2nd.MD to Improve Member Healthcare Cost, Quality, and Outcomes - PRNewswire - September 19th, 2020
- Novus Therapeutics Announces Acquisition of Anelixis Therapeutics - Business Wire - September 19th, 2020
- Pace toddler wasn't supposed to survive. Thanks to wonder drug, parents say he's thriving - Pensacola News Journal - September 8th, 2020
- CRISPR can help combat the troubling immune response against gene therapy - The Conversation US - September 6th, 2020
- How Is Ovarian Cancer Diagnosed? Everything You Need To Know - NDTV Doctor - September 6th, 2020
- Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer |... - September 6th, 2020
- Gilmore Health: A Q&A Session on Genetic Diseases With Dr. Sony Sherpa - Gilmore Health News - September 6th, 2020
- Our teenage son is turning to stone and is becoming entombed in his own body - The Sun - August 28th, 2020
- Gene Therapy: IT Meets Medicine, But Who Is In Charge? - Walter Bradley Center for Natural and Artificial Intelligence - August 24th, 2020
- Edited Transcript of ISEE.OQ earnings conference call or presentation 5-Aug-20 12:00pm GMT - Yahoo Finance - August 6th, 2020
- Opinion: With any COVID-19 vaccine, humanity will face its biggest moral test - The Province - August 4th, 2020
- These Companies Are Seeking a Cure for Sickle Cell. And Its Just the Beginning for Some Gene Therapy Stocks. - Barron's - July 31st, 2020
- FDA Approves Combination Therapy for Treating Advanced Melanoma - Pharmacy Times - July 31st, 2020
- How Can Technology Help Fight the COVID-19 Pandemic? - IoT For All - July 31st, 2020
- Thomas Jefferson University doctor to be honored at W&J commencement - Observer-Reporter - July 30th, 2020
- First Edition: July 27, 2020 - Kaiser Health News - July 30th, 2020
- These are the most valued tech startups in France in 2020 - Silicon Canals - July 7th, 2020
- What's a life worth in dollars and cents? Should that influence who gets treated for expensive disease treatments? - Genetic Literacy Project - July 1st, 2020
- FDA Approves Genentech's Phesgo (Fixed-dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-positive Breast Cancer -... - July 1st, 2020
- Conversations Between Patient and Oncologist Are Important in Avoiding 'Common Mistake' When Treating CLL - Curetoday.com - June 28th, 2020
- Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma - The Institute of Cancer Research - June 28th, 2020
- Family Of Dying Santa Clarita Teen Pleads With Community For Donations To Fund Life-Saving Treatment - KHTS Radio - June 24th, 2020
- Hungarian Neurobiologist Botond Roska to Receive This Year's Krber European Science Prize - Hungary Today - June 24th, 2020
- Quarterly summary: the COVID-19 lockdown and the importance of scientists - University Affairs - June 24th, 2020
- Flames assistant GM continues to defy the odds in his battle against ALS - CTV News - June 23rd, 2020
- 3 Reasons to Go Long Crispr Therapeutics - InvestorPlace - June 23rd, 2020
- GRIN Disorder, Kidney Failure and Fathers Day How One Family is Surviving it All - CBC.ca - June 23rd, 2020
- Gene Therapy: Regal Profits From Curing "The Royal Disease"? - Sick Economics - June 18th, 2020
- Cancer patients and doctors carry on with clinical trials during Covid-19 - STAT - June 18th, 2020
- Genentech's Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response,... - June 18th, 2020
- They discover how to stop tumor growth in breast cancer - Explica - June 5th, 2020